Keywords
How to Cite
Abstract
Cardiovascular diseases (CVDs) are the leading cause of death worldwide which results from the impaired function of the heart and blood vessels. The most common CVDs are coronary heart and stroke. The main clinical manifestation of these diseases is the formation of atherosclerosis which is associated with the change of blood lipid levels. Simvastatin is widely used in patients with impaired lipid levels in the blood. The study was a descriptive research with a retrospective approach on medical record data (n=64) taken from Palu City, Central Sulawesi, Indonesia. The variables included in this study were gender, age, diagnosis, co-medication, lipid profile including total cholesterol, LDL, triglycerides, and HDL in patients with CVDs receiving simvastatin. In the study, sixty-four patients of CVDs met the inclusion and exclusion criteria. This study suggested that simvastatin achieved to normalize the blood lipid levels, including total cholesterol in forty-four patients (68.75%), LDL in forty-nine patients (80.3%), triglycerides in fifty-nine patients (92.19%), and HDL in fifty-two patients (81.25%). The use of simvastatin in patients with CVDs managed to lower total cholesterol, LDL, and triglycerides, as well as increase the HDL level.
References
Ministry of Health. Information Data Center Ministry of Health. Ministry of Health Republic of Indonesia. Jakarta: 2013a.
World Health Organization [homepage on the Internet
Muttaqin A. Nursing Care of Clients with Impaired Cardiovascular System. Salemba Medika. Jakarta 2008.
Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. A Pathophysiologic Approach. In: Pharmacotherapy. 7th Edition. New York: The McGraw-Hill Companies 2011; p. 33.
Ministry of Health. Basic Health Research. Ministry of Health Republic of Indonesia. Jakarta 2013b.
Grundy SM, Cleeman JI, Merz NB, Brewer B, Clark LT, Smith SC, Stone N. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004.
Munchid A, Umar F, Budiarti LE, Satifa O, Brata C, Bakhtiar L. Pharmaceutical Care for Dislipidemia Disease. Directorate of Community Pharmacy and Clinic. Directorate General of Pharmaceutical and Medical Devices. Ministry of Health 2006.
Page C, Curtis M, Walker M, Hoffman B. Integrated Pharmacology 3rd Ed. Mosby Elsevier 2006.
Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacotherapy 1995.
Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy Handbook Nineth. USA: McGraw-Hill Company 2015.
Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA. AACE Task Force for the Management of Hyperlipidemia and Prevention of Atherosclerosis Writing Committee. Endocr Pract 2012.
Association of Indonesian Cardiovascular Specialist Doctors. Guidelines for the Treatment of Hyperlipidemia in Cardiovascular Disease. First Edition. Jakarta: Association of Cardiovascular Specialist Doctors Indonesia 2015.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2018 Safarudin, Alwiyah Mukaddas, Faraditha Amalia , Amelia Rumi